

Resource Summary Report

Generated by ASWG on Aug 15, 2026

Recombinant Anti-CD38 antibody [EPR4106]

RRID:AB_10890803

Type: Antibody

Proper Citation

Abcam Cat# ab108403, RRID:AB_10890803

Antibody Information

URL: http://antibodyregistry.org/AB_10890803

Proper Citation: Abcam Cat# ab108403, RRID:AB_10890803

Target Antigen: CD38

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-P, Flow Cyt

Antibody Name: Recombinant Anti-CD38 antibody [EPR4106]

Description: This recombinant monoclonal targets CD38

Target Organism: human

Clone ID: EPR4106

Antibody ID: AB_10890803

Vendor: Abcam

Catalog Number: ab108403

Record Creation Time: 20250819T215530+0000

Record Last Update: 20250820T003237+0000

Ratings and Alerts

- Used for cytometry time of flight assay by the Human Islet Research Network community. Contact(s): [Clive Wasserfall](#), [Irina Kusmartseva](#), [Harry Nick](#), [Fabrizio Thorel](#), [Pedro Herrera](#), [Mark Atkinson](#), [Bernd Bodenmiller](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for Recombinant Anti-CD38 antibody [EPR4106].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Zhao W, et al. (2026) NAD-dependent redox control enables endothelial quiescence and vascular stabilization during angiogenesis. *Cell metabolism*, 38(7), 1478.

Alabarse PG, et al. (2024) The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target. *Inflammation research : official journal of the European Histamine Research Society ... [et al.]*.

Huang Y, et al. (2024) Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. *Cell reports. Medicine*, 5(2), 101400.

Damond N, et al. (2019) A Map of Human Type 1 Diabetes Progression by Imaging Mass Cytometry. *Cell metabolism*, 29(3), 755.

Tarrag?? MG, et al. (2018) A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD⁺ Decline. *Cell metabolism*, 27(5), 1081.